Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKing, Tracy-
dc.contributor.authorJagger, Jacqueline-
dc.contributor.authorWood, Jodie-
dc.contributor.authorWoodrow, Carmel-
dc.contributor.authorSnowden, Alicia-
dc.contributor.authorHaines, Sally-
dc.contributor.authorCrosbie, Christina-
dc.contributor.authorHoudyk, Kristen-
dc.identifier.citationAsia-Pacific journal of oncology nursing 2018; 5(3): 270-284-
dc.description.abstractPatients with multiple myeloma (MM) are typically of an advanced age and may have significant co-existing medical conditions. They have often had multiple lines of therapy and as such experience disease-related effects alongside associated treatment toxicities. Daratumumab is a monoclonal antibody approved for the treatment of MM in the relapsed/refractory setting. Clinical studies found that daratumumab showed good tolerability as a monotherapy and in combination with current standard therapies. However, the administration of daratumumab does require specific management considerations. It is administered as an intravenous infusion and infusion-related reactions (IRRs) may occur. Daratumumab also interferes with routine blood transfusion tests, giving false positives for the indirect antiglobulin test. This article highlights key nursing care considerations and practical management aspects to improve the treatment experience of patients receiving daratumumab infusions. Pretreatment aspects, patient education, pre- and post-medication, daratumumab administration, and the management of IRRs are discussed. An IRR management sheet that could be used by nurses and a patient information sheet are located at the end of this article.-
dc.subjectinfusion-related reaction-
dc.subjectmultiple myeloma-
dc.titleBest Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion.-
dc.typeJournal Article-
dc.identifier.journaltitleAsia-Pacific journal of oncology nursing-
dc.identifier.affiliationInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia-
dc.identifier.affiliationCancer Services, Gosford Hospital, Gosford, NSW, Australia-
dc.identifier.affiliationCancer Services, Flinders Medical Centre, Adelaide, SA, Australia-
dc.identifier.affiliationDivision of Cancer Services, Princess Alexandra Hospital, Brisbane, QLD, Australia-
dc.identifier.affiliationPrecision Haematology, Melbourne, Australia-
dc.identifier.affiliationHaematology and Stem Cell Transplantation Service, The Alfred Hospital, Melbourne, Australia-
dc.identifier.affiliationHaematology, St. Charles Gairdner Hospital, Nedlands WA, Australia-
dc.identifier.affiliationCancer Clinical Trials Centre, Austin Health, Heidelberg, Victoria, Australia-
dc.type.austinJournal Article-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Feb 5, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.